Findings of a Biosimilar Trastuzumab Study in Patients with HER2-Positive Breast Cancer
September 21st 2016Francisco Esteva, director, breast medical oncology program, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the findings of a biosimilar trastuzumab study in patients with HER2-positive breast cancer.